Text Size
25 studies found for:    GIST | Open Studies | United States

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Condition: 3rd Line GIST
Intervention: Drug: ST571 + BYL719
2 Recruiting A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Condition: 3rd Line GIST
Intervention: Drug: STI571 + BKM120
3 Recruiting A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation;   Drug: sunitinib malate
4 Recruiting Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
5 Recruiting A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: masitinib (AB1010);   Drug: imatinib
6 Recruiting Phase II Study of Crenolanib (CP-868,596), for the Treatment of Patients With Advanced Gastrointestinal Stromal Tumors With the D842-related Mutations and Deletions in the PDGFRA Gene
Condition: D842-related Mutant GIST
Intervention: Drug: Crenolanib besylate (CP-868,596-26), Dose: 140mg BID
7 Recruiting Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
Condition: Gastric Cancers
Intervention:
8 Recruiting Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Conditions: Advanced Renal Cell Carcinoma;   Gastrointestinal Stromal Tumors;   Pancreatic Neuroendocrine Tumors
Intervention: Drug: TH-302
9 Not yet recruiting Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Conditions: Pancreatic Cyst;   Pancreatic Neoplasms;   Pancreatic Adenoma;   Pancreatic Cancer;   Pancreatic Islet Cell Tumors;   Lymph Node;   Lymphadenopathy;   GIST
Intervention: Device: EUS-FNA: Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
10 Recruiting Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot be Removed by Surgery or Are Metastatic
Conditions: Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Endometrial Stromal Sarcoma;   Ewing Sarcoma of Bone;   Extraosseous Ewing Sarcoma;   Gastrointestinal Stromal Tumor;   Mast Cell Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: dasatinib;   Biological: ipilimumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Recruiting Treatment of Social Competence After Traumatic Brain Injury
Condition: Traumatic Brain Injury
Interventions: Behavioral: Group Interactive Structured Treatment;   Behavioral: Alternative Intervention
12 Not yet recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
13 Recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107
14 Recruiting Permission to Collect Blood Over Time for Research
Conditions: Pancreatic Cancer;   Gastrointestinal Neoplasms;   Colon Rectal Cancer Adenocarcinoma;   Esophageal Cancer;   Gall Bladder Cancer;   Gastric (Stomach) Cancer;   Gastrooesophageal Cancer;   Gastrointestinal Stromal Tumor (GIST);   Hepatobiliary Neoplasm;   Liver Carcinoma;   Gallbladder Carcinoma;   Bile Duct Carcinoma;   Carcinoma of the Large Intestine;   Anal Cancer
Intervention: Procedure: Observation
15 Recruiting Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Conditions: Stomach Cancer;   Gastro-Esophageal(GE) Junction Cancer;   Gastric (Stomach) Cancer;   Esophageal Cancer;   Gastrointestinal Stromal Tumor (GIST)
Interventions: Procedure: Blood draw;   Procedure: Tissue tumor biopsy
16 Recruiting Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Conditions: Stomach Cancer;   Gastric (Stomach) Cancer;   Neoplasm of Cardioesophageal Junction;   Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: bevacizumab;   Drug: carboplatin;   Drug: capecitabine
17 Recruiting Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Conditions: Malignant Solid Tumour;   Breast Cancer;   Malignant Tumor of Colon;   GIST;   Ovarian Cancer
Intervention: Biological: HER-2 vaccine
18 Recruiting A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Conditions: Metastatic Breast Cancer;   Advanced Breast Cancer;   Advanced Gastric Cancer;   Advanced/Metastatic Non-small Cell Lung Cancer;   Gastrointestinal Stromal Tumor;   Hepatocellular Carcinoma;   Metastatic Castration-resistant Prostate Cancer;   Metastatic Renal Cell Cancer;   Non Small Cell Lung Cancer;   Pancreatic Islet Cell Carcinoma;   Pancreatic Neuroendocrine Tumor;   Thyroid Cancer
Intervention: Drug: sunitinib
19 Recruiting Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
Conditions: Adult Alveolar Soft-part Sarcoma;   Adult Angiosarcoma;   Adult Desmoplastic Small Round Cell Tumor;   Adult Epithelioid Hemangioendothelioma;   Adult Epithelioid Sarcoma;   Adult Extraskeletal Chondrosarcoma;   Adult Extraskeletal Osteosarcoma;   Adult Fibrosarcoma;   Adult Leiomyosarcoma;   Adult Liposarcoma;   Adult Malignant Fibrous Histiocytoma;   Adult Malignant Mesenchymoma;   Adult Neurofibrosarcoma;   Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Dermatofibrosarcoma Protuberans;   Gastrointestinal Stromal Tumor;   Metastatic Adult Malignant Fibrous Histiocytoma of Bone;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Ovarian Sarcoma;   Recurrent Adult Malignant Fibrous Histiocytoma of Bone;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Kaposi Sarcoma;   Recurrent Osteosarcoma;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage III Uterine Sarcoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Uterine Sarcoma
Interventions: Drug: vismodegib;   Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis;   Other: pharmacological study
20 Not yet recruiting Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Condition: Tumor Pathway Activations Inhibited by Dovitinib
Intervention: Drug: Dovitinib (TKI258)
To Top

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
† Indicates status has not been verified in more than two years